Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches

Glioblastoma is the most common primary adult brain tumour, and despite optimal treatment, the median survival is 12–15 months. Patients with matched recurrent glioblastomas were investigated to try to find actionable mutations. Tumours were profiled using a validated DNA-based gene panel. Copy numb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, H. P., McInerney, C. E., Schrimpf, D., Sahm, F., Stupnikov, A., Wadsley, M., Wragg, C., White, P., Prise, K. M., McArt, D. G., Kurian, K. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012245/
https://www.ncbi.nlm.nih.gov/pubmed/32082376
http://dx.doi.org/10.1155/2019/4878547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012245/
https://www.ncbi.nlm.nih.gov/pubmed/32082376
http://dx.doi.org/10.1155/2019/4878547

Ejemplares similares